Join us for an insightful webinar discussion on the use of precision
oncology and breast cancer management in the Asia-Pacific (APAC) region. This event will
feature leading oncologists who will share their clinical
expertise and discuss the application of Comprehensive Genomic Profiling (CGP) and Molecular Tumor Board (MTB),
as well as updated breast cancer testing and treatment in APAC region:
Details
Time
16:00 - 19:30
Topics
Precision oncology realization: Right diagnosis at the right time for all patients
Tissue biopsy and liquid biopsy: Complementary approaches in cancer management
Implementation of MTBs for better clinical outcomes: APAC MTB consensus publication sharing
Novel PI3Kα Inhibitor in Hormone Receptor–Positive, HER2-Negative Breast Cancer
Hear from experts on their clinical experience using CGP, MTB, and their value in precision oncology
Get updates on the new biomarker and genomic signatures, and tissue-based vs liquid-based testing
Learn about upcoming PIK3CA testing and treatment in breast cancer
Speakers
Dr. Herbert Loong
Deputy Medical Director, Phase 1 Clinical Trials Centre, The Chinese University of Hong Kong
Dr. Linda Mileshkin
Peter MacCallum Cancer Centre
Dr. Sewanti Limaye
Reliance Foundation Hospital & Research Center, India
Dr. Dejan Juric
Director, Termeer Center for Targeted Therapies & Investigational Cancer Therapeutics Program, Massachusetts General Hospital Cancer Centre
Moderators
Dr. Daniel Chan
CON Cancer Centre Singapore
Dr. Yoon Sim Yap
National Cancer Centre Singapore
Agenda
Time
Topic
Speakers
16:00 - 16:10
Opening remarks
Lance Little Head of Region Asia Pacific, Roche Diagnostics Ltd.
16:10 - 16:40
Trends and Challenges in Molecular Tumour Board Implementation in the Asia-Pacific Region: APAC MTB Expert Consensus Statement
Dr. Herbert Loong
16:40 - 17:10
Unlocking the power of liquid biopsy-based profiling in clinical practice
Dr. Linda Mileshkin
17:10 - 17:40
Panel Discussion: Facilitating access to Molecular Guided Treatment Options by leveraging advancements in genomic profiling and molecular tumour boards
Panelists
17:40 - 17:55
Break
All
17:55 - 18:25
Clinical Utility and Benefits of CGP: Evolving roles of CGP in ovarian cancer and breast cancer
Dr. Sewanti Limaye
18:25 - 18:55
Targeting PIK3CA Mutations in Breast Cancer: From Testing to Therapeutic Strategies
Dr. Dejan Juric
18:55 - 19:25
Panel Discussion: management of novel genes in breast cancer
Panelists
19:25 - 19:30
Closing
Ahmed Elhusseiny Area Head APAC, Roche Pharmaceuticals
This material represents personal viewpoint and is intended to
promote the communication and exchange of medical information, and
shall be used by healthcare professionals as a reference only.
This material may contain medicinal products or clinical
indications that have not yet been approved in your country.
Please refer to the locally approved package insert for detailed
prescription information.
Be the first to receive updates, event opportunities, and thought leadership insights.
The information contained in this website is intended for healthcare professionals only.
Click “OK” if you are a healthcare professional.
